MyMD Pharmaceuticals Inc (MYMD)
2.520
+0.27
(+12.00%)
USD |
NASDAQ |
Apr 18, 16:00
2.495
-0.02
(-0.99%)
After-Hours: 20:00
MyMD Pharmaceuticals Cash from Investing (TTM): 1.846M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.846M |
| September 30, 2023 | -1.401M |
| June 30, 2023 | -7.030M |
| March 31, 2023 | -7.361M |
| December 31, 2022 | 6.913M |
| Date | Value |
|---|---|
| September 30, 2022 | 7.224M |
| June 30, 2022 | 14.99M |
| March 31, 2022 | 22.85M |
| December 31, 2021 | 19.85M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-7.361M
Minimum
Mar 2023
22.85M
Maximum
Mar 2022
6.431M
Average
6.913M
Median
Dec 2022
Cash from Investing (TTM) Benchmarks
| Acrivon Therapeutics Inc | 50.72M |
| Vincerx Pharma Inc | 41.50M |
| CEL-SCI Corp | -0.3835M |
| AIM ImmunoTech Inc | -0.832M |
| IGC Pharma Inc | -0.236M |